Serum osteoprotegerin correlates with age and bone mass in postmenopausal, but not in fertile age women

G. Mainini, M. Incoronato, L. Urso, C. Scaffa

Research output: Contribution to journalArticlepeer-review


Purpose of investigation: Osteoprotegerin (OPG) and receptor activator of nuclear factor κB ligand (RANKL) are bone turnover modulators expressed by osteoblasts. The aim of this study was to assess the relationship between the circulating OPG/RANKL system, age and bone mass, in fertile age and postmenopausal women. Methods: In this cross-sectional observational study on 48 patients (fertile age, n = 22; postmenopause, n = 26), we investigated the correlation between serum OPG and RANKL, age and bone mineral density (BMD). Serum concentrations of OPG and RANKL were determined by enzyme-linked immunosorbent assay (ELISA); estimate BMD evaluation was performed with heel quantitative ultrasonometry (QUS). Results: Serum OPG significantly increased (p = 0.003) and serum RANKL significantly decreased (p = 0.002), in the postmenopausal group compared to fertile age women. A significant correlation of serum OPG with age (r S = 0.39, p = 0.047) and BMD (r S = 0.45, p = 0.023) in postmenopausal women, and between RANKL and BMD (r S = 0.48, p = 0.024) in fertile age was found. Conclusion: These data demonstrate in vivo that the OPG/RANKL system is significantly associated with menopausal status and could play a role in postmenopausal osteoporosis.

Original languageEnglish
Pages (from-to)355-359
Number of pages5
JournalClinical and Experimental Obstetrics and Gynecology
Issue number4
Publication statusPublished - 2011


  • Menopause
  • Osteoporosis
  • Osteoprotegerin

ASJC Scopus subject areas

  • Obstetrics and Gynaecology
  • Reproductive Medicine


Dive into the research topics of 'Serum osteoprotegerin correlates with age and bone mass in postmenopausal, but not in fertile age women'. Together they form a unique fingerprint.

Cite this